MedTech | Switzerland

Challenge

A global medical technology company faced significant pressure from ongoing tariff reforms, with proposed reimbursement structures risking disadvantaging quality-driven treatment methods. The evolving framework created uncertainty over future market access and pricing dynamics.

Approach

We acted as a strategic partner across policy, market access and communications, aligning internal stakeholders and translating regulatory developments into concrete positioning.

• Built a detailed stakeholder map across the Federal Office of Public Health, parliamentary health committees (SGK-N / SGK-S), insurers and medical societies
• Conducted targeted outreach to parliamentarians and senior administrative stakeholders, including bilateral briefings and background discussions
• Supported the development of positioning materials and policy briefs, framing innovation in terms of quality, efficiency and system value
• Coordinated clinical expert input to strengthen credibility in consultations
• Designed and facilitated policy roundtables, bringing together decision-makers, providers and payers
• Provided continuous strategic guidance, adapting positioning based on political dynamics and negotiation progress

Outcome

• Reduction of pressure on reimbursement levels and increased consideration of differentiated approaches
• Greater recognition of quality-related risks in tariff design among policymakers and administration
• Strengthened positioning of the client as a credible and constructive stakeholder in the reform process
• Sustained access to decision-makers and continued involvement in policy discussions at federal level